Moraga Biotechnology Corporation, an adult stem cell company based in Los Angeles, California, announces the discovery of its proprietary Blastomere-Like Stem Cells (BLSCs) circulating in the peripheral blood of mammals. The Company's scientists found that these adult stem cells were able to differentiate into most tissues and organs of the body.
The Company's scientists have developed a proprietary and cost-effective method for isolating and purifying large numbers of its primitive embryonic- like stem cells from the blood without ex vivo expansion. Moraga recently announced that its BLSCs were found in large numbers throughout the body. The Company believes this new discovery is a major breakthrough for finding large numbers of primitive adult stem cells circulating in the blood.
Moraga's chief executive, Dr. John F. Wong, noted that the ability to isolate these primitive embryonic-like stem cells in peripheral blood allows the Company to enter the stem cell banking business in the near future. With this new method for isolating stem cells, the Company will be able to bank an individual's stem cells by simply withdrawing a sample of their blood. The Company intends in the very near future to establish processing centers to which a donor's blood sample is shipped; the blood is processed; and, the stem cells are isolated. The BLSCs are then stored at the center for future therapeutic and diagnostic use. Dr. Wong further stated that "by circumventing the expensive process of isolating and expanding the stem cells outside the body, the Company can now travel down a shorter path towards developing a near-term solution for autologous stem cell-based therapies, from which its BLSCs may be used for treating various forms of diseases such as heart attacks, Parkinson's disease and stroke."
For more information on Moraga Biotechnology Corp.
哺乳动物外周血中发现原始成年干细胞
核心摘要:
研究人员发现哺乳动物外周血中存在原始成年干细胞(Blastomere-Like Stem Cells, BLSCs),这些干细胞能够分化为大多数组织和器官。科学家们开发了一种专有的、经济有效的方法,从血液中分离和纯化大量的原始胚胎样干细胞,无需体外扩增。这一发现为找到大量原始成年干细胞提供了新的途径,有望用于干细胞银行业务和自体干细胞治疗。